CANADA LIFE ASSURANCE Co Trims Stock Position in Progyny, Inc. (NASDAQ:PGNY)

CANADA LIFE ASSURANCE Co cut its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 5.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 85,630 shares of the company’s stock after selling 5,173 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in Progyny were worth $1,479,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PGNY. River Road Asset Management LLC bought a new position in shares of Progyny during the fourth quarter valued at approximately $25,529,000. Pacer Advisors Inc. boosted its stake in shares of Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock valued at $63,414,000 after purchasing an additional 1,183,558 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after purchasing an additional 695,740 shares in the last quarter. Barclays PLC boosted its stake in shares of Progyny by 95.7% during the fourth quarter. Barclays PLC now owns 1,382,205 shares of the company’s stock valued at $23,843,000 after purchasing an additional 676,048 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its stake in shares of Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after purchasing an additional 456,853 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Performance

Shares of PGNY stock opened at $22.75 on Tuesday. The stock’s 50-day simple moving average is $21.92 and its 200-day simple moving average is $19.14. The firm has a market capitalization of $1.95 billion, a PE ratio of 39.22, a P/E/G ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $33.84.

Analyst Ratings Changes

PGNY has been the topic of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America raised their target price on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group upped their price target on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Finally, BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Monday, March 31st. Eight equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.